X4 Pharmaceuticals (XFOR) Jefferies Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Jefferies Global Healthcare Conference summary
16 Nov, 2026Program and clinical rationale
Mavorixafor blocks CXCR4 to promote neutrophil movement from bone marrow into blood; the intended benefit is fewer infections in primary chronic neutropenia.
Patients face recurrent infections and restrictions on daily life; current options include antibiotics and G-CSF injections, which can cause bone pain, fatigue and concern about long-term risks.
In a 23-patient phase II study, mavorixafor maintained ANC above 1,500 in monotherapy patients over three to six months; G-CSF dosing fell by about 70% in treated patients, with G-CSF eliminated for some.
GI toxicity can occur in the first weeks of therapy and is managed with over-the-counter medication, including anti-diarrheals such as loperamide.
4WARD pivotal trial
Phase III, double-blind, placebo-controlled 4WARD tests infection reduction and ANC increase as co-primary endpoints over 12 months in 126 patients.
Infection endpoint is powered for at least a 30% reduction at 89% power; ANC endpoint is an increase of 500 cells/µL on at least three occasions, with 93% power.
Enrollment is expected to finish by year-end 2026; after 12 months of follow-up, data are expected in Q1 2028. A successful trial could support an sNDA for primary chronic neutropenia.
Enrolled population has median age 36, median ANC 583, 37% using G-CSF, and 68% with at least three infections; entry requires at least two infections in the prior 12 months.
G-CSF dose is fixed during 4WARD; the FDA requested enrollment of patients likely to show a treatment difference.
G-CSF reduction and launch preparation
4STEPS will evaluate G-CSF reduction after mavorixafor initiation: an eight-week run-in followed by 24 weeks with four potential 25% dose reductions.
4STEPS is expected to enroll its first patient early next year, with primary data expected in Q1 2028; results are intended to guide G-CSF use at a potential launch in late 2028 or early 2029.
Physician survey feedback indicated interest in differentiated oral therapy and willingness to prescribe mavorixafor if successful.
Latest events from X4 Pharmaceuticals
- 4WARD enrollment targets year-end 2026, with topline data expected in Q1 2028.XFOR
Stifel 2026 Healthcare Conference 2026 - 4WARD enrollment is targeted for year-end 2026; top-line results are expected in Q1 2028.XFOR
3rd Annual Guggenheim Healthcare Innovation Conference - Higher product sales and 4WARD progress accompany debt refinancing and runway into Q1 2029.XFOR
Q3 2026 - Mavorixafor’s PCN opportunity pairs a ~15,000-patient base with Q1 2028 readouts.XFOR
Investor Day 2026 - 4WARD topline data are expected in H1 2028, backed by Phase 2 evidence of ANC gains and reduced G-CSF use.XFOR
Corporate presentation - Phase III enrollment nears completion, with launch targeted for late 2028 or early 2029.XFOR
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue was $8.8M, net loss improved, and cash runway extends into 2029.XFOR
Q2 2026 - XOLREMDI launch gains traction as Phase 3 CN trial advances and global expansion plans progress.XFOR
Stifel 2024 Healthcare Conference - Q2 net income hit $90.8M on $105M PRV sale and XOLREMDI U.S. launch.XFOR
Q2 2024 - Mavorixafor durably increased ANC and showed good tolerability in chronic neutropenia Phase 2.XFOR
Study Update